This aberration seems to be different from several previous reports of somatic TP53 mutations described in a small subset (~7–15%) of cisplatin-resistant or relapsed GCT and more frequently among patients with IGCCCG poor-risk group and having a mediastinal non-seminoma primary tumour site [34,44]. This evidence concerns the gene TP53 and neoplasm.